Correlation Between Pharvaris and Viracta Therapeutics

Can any of the company-specific risk be diversified away by investing in both Pharvaris and Viracta Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pharvaris and Viracta Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pharvaris BV and Viracta Therapeutics, you can compare the effects of market volatilities on Pharvaris and Viracta Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pharvaris with a short position of Viracta Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pharvaris and Viracta Therapeutics.

Diversification Opportunities for Pharvaris and Viracta Therapeutics

0.2

Correlation Coefficient

Pharvaris  Viracta Therapeutics

Modest diversification

The 3 months correlation between Pharvaris and Viracta is 0.2. Overlapping area represents the amount of risk that can be diversified away by holding Pharvaris BV and Viracta Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viracta Therapeutics and Pharvaris is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pharvaris BV are associated (or correlated) with Viracta Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viracta Therapeutics has no effect on the direction of Pharvaris i.e., Pharvaris and Viracta Therapeutics go up and down completely randomly.

Pair Corralation between Pharvaris and Viracta Therapeutics

Given the investment horizon of 90 days Pharvaris BV is expected to generate 0.18 times more return on investment than Viracta Therapeutics. However, Pharvaris BV is 5.5 times less risky than Viracta Therapeutics. It trades about -0.09 of its potential returns per unit of risk. Viracta Therapeutics is currently generating about -0.28 per unit of risk. If you would invest  1,902  in Pharvaris BV on December 30, 2024 and sell it today you would lose (322.00) from holding Pharvaris BV or give up 16.93% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	41.94%
Values	Daily Returns

Pharvaris BV  vs.  Viracta Therapeutics

Pharvaris BV

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pharvaris BV has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Viracta Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Pharvaris and Viracta Therapeutics

The main advantage of trading using opposite Pharvaris and Viracta Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pharvaris position performs unexpectedly, Viracta Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viracta Therapeutics will offset losses from the drop in Viracta Therapeutics' long position.

The idea behind Pharvaris BV and Viracta Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.